Cancer Research Institute's video: Ovarian Cancer Immunotherapy with Dr Kunle Odunsi

Dr. Kunle Odunsi discusses the latest breakthroughs and future promise of immunotherapy for ovarian cancer patients. https://www.cancerresearch.org/virtualsummit Globally, ovarian cancer is diagnosed in an estimated 300,000 women each year. While significant advances have been made in surgical and chemo-based treatments for ovarian cancer, the survival rates have only modestly improved. Immunotherapy for ovarian cancer shows tremendous potential for addressing this devastating disease. https://www.cancerresearch.org/immunotherapy/cancer-types/ovarian-cancer Dr. Kunle Odunsi, a gynecologic oncologist specializing in cancer immunotherapy at Roswell Park Comprehensive Cancer Center, discusses details of immunotherapy clinical trials in ovarian cancer currently underway and takes your questions about new treatments in gynecologic cancers. In this video, he answers questions about: - Adoptive T cell therapies, such as CAR T cell therapy - Cancer vaccines, including neoantigen vaccines - Biomarkers and genomic sequencing - Cancer mutations, such as BRCA and Lynch syndrome - Cancer immunotherapy clinical trials - Combination therapies, such as chemotherapy + immunotherapy or PARP inhibitors + immunotherapy - Cancer immunotherapy side effects - Overall health during cancer treatment, including age - Questions to ask your oncologist - Oncolytic virus therapy - Other gynecologic cancers, including cervical and uterine (endometrial) cancer Dr. Odunsi is the Deputy Director and The Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy at Roswell Park Comprehensive Cancer Center, where he also serves as the Chair of the Department of Gynecologic Oncology, The M. Steven Piver Professor of Gynecologic Oncology, and the Executive Director of the Center for Immunotherapy. There, he oversees all scientific and clinical research-related initiatives, including the transfer of scientific discoveries into clinical settings. Dr. Odunsi is a member of the National Academy of Medicine and has made significant research contributions, including the characterization of tumor antigens and development of novel immunotherapy and cellular-therapy approaches for treating various solid tumor cancers. He is the Chair-Elect of the AACR Cancer Immunology Working Group (CIMM) and a Society for Immunotherapy of Cancer (SITC) At-Large Director. Dr. Odunsi is a fellow of the Royal College of Obstetricians and Gynecologists and the American College of Obstetricians and Gynecologists. He is a member of CRI’s Scientific Advisory Council, member of CRI’s Clinical Leadership Committee, and serves on CRI’s CLIP Grant Review Committee. https://www.cancerresearch.org/about-cri/scientific-leadership/associate-directors/kunle-odunsi The 2020 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.